secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0000950170-24-089939
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO and CMO depart; MEI Pharma evaluates wind-down; CFO becomes Acting CEO
--------------------------------------------------------------------------

- CEO David M. Urso and CMO Richard G. Ghalie depart effective Aug 1, 2024; eligible for severance (12 mo salary, COBRA, prorated bonus, accelerated vesting).
- Executives signed consulting agreements ($475/hr) to assist asset sales; Urso eligible for 8% success fee, Ghalie 2% on net proceeds from voruciclib, ME-344, zandelisib.
- CFO Justin J. File appointed Acting CEO; base salary raised to $550k, bonus target increased to 50%, and eligible for success fee based on closing cash balance.
- Company continues evaluating strategic alternatives including possible wind-down to maximize asset value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024089939/0000950170-24-089939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024089939/meip-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer